90 related articles for article (PubMed ID: 21331614)
1. Quantitative analysis of matrix metalloproteinase-2 mRNA expression in central and peripheral regions of gliomas.
Brell M; Ibáñez J; Felpete A; Burguera B; Frontera M; Couce ME
Brain Tumor Pathol; 2011 Apr; 28(2):137-44. PubMed ID: 21331614
[TBL] [Abstract][Full Text] [Related]
2. Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas.
Stojic J; Hagemann C; Haas S; Herbold C; Kühnel S; Gerngras S; Roggendorf W; Roosen K; Vince GH
Neurosci Res; 2008 Jan; 60(1):40-9. PubMed ID: 17980449
[TBL] [Abstract][Full Text] [Related]
3. Gelatinolytic activity of matrix metalloproteinase-2 and matrix metalloproteinase-9 in rat brain after implantation of 9L rat glioma cells.
Zhao JX; Yang LP; Wang YF; Qin LP; Liu DQ; Bai CX; Nan X; Shi SS; Pei XJ
Eur J Neurol; 2007 May; 14(5):510-6. PubMed ID: 17437609
[TBL] [Abstract][Full Text] [Related]
4. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro.
Yamamoto M; Mohanam S; Sawaya R; Fuller GN; Seiki M; Sato H; Gokaslan ZL; Liotta LA; Nicolson GL; Rao JS
Cancer Res; 1996 Jan; 56(2):384-92. PubMed ID: 8542596
[TBL] [Abstract][Full Text] [Related]
6. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
[TBL] [Abstract][Full Text] [Related]
7. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.
Forsyth PA; Wong H; Laing TD; Rewcastle NB; Morris DG; Muzik H; Leco KJ; Johnston RN; Brasher PM; Sutherland G; Edwards DR
Br J Cancer; 1999 Apr; 79(11-12):1828-35. PubMed ID: 10206300
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
[TBL] [Abstract][Full Text] [Related]
9. High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma.
Cheng S; Tada M; Hida Y; Asano T; Kuramae T; Takemoto N; Hamada J; Miyamoto M; Hirano S; Kondo S; Moriuchi T
J Surg Res; 2008 May; 146(1):104-9. PubMed ID: 17663001
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas.
Liu W; Kunishio K; Matsumoto Y; Okada M; Nagao S
J Clin Neurosci; 2005 Sep; 12(7):791-4. PubMed ID: 16198918
[TBL] [Abstract][Full Text] [Related]
11. The value and correlation between PRL-3 expression and matrix metalloproteinase activity and expression in human gliomas.
Kong L; Li Q; Wang L; Liu Z; Sun T
Neuropathology; 2007 Dec; 27(6):516-21. PubMed ID: 18021371
[TBL] [Abstract][Full Text] [Related]
12. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
13. Differential expression and localization of TIMP-1 and TIMP-4 in human gliomas.
Groft LL; Muzik H; Rewcastle NB; Johnston RN; Knäuper V; Lafleur MA; Forsyth PA; Edwards DR
Br J Cancer; 2001 Jul; 85(1):55-63. PubMed ID: 11437402
[TBL] [Abstract][Full Text] [Related]
14. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
[TBL] [Abstract][Full Text] [Related]
15. Astrocyte elevated gene-1 upregulates matrix metalloproteinase-9 and induces human glioma invasion.
Liu L; Wu J; Ying Z; Chen B; Han A; Liang Y; Song L; Yuan J; Li J; Li M
Cancer Res; 2010 May; 70(9):3750-9. PubMed ID: 20388776
[TBL] [Abstract][Full Text] [Related]
16. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
17. [Extracellular matrix of cerebral tumors with different invasiveness].
Klekner A; Varga I; Bognár L; Hutóczki G; Kenyeres A; Tóth J; Hanzély Z; Scholtz B
Ideggyogy Sz; 2010 Jan; 63(1-2):38-43. PubMed ID: 20420122
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.
Määttä M; Soini Y; Liakka A; Autio-Harmainen H
Clin Cancer Res; 2000 Jul; 6(7):2726-34. PubMed ID: 10914717
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer.
Papathoma AS; Petraki C; Grigorakis A; Papakonstantinou H; Karavana V; Stefanakis S; Sotsiou F; Pintzas A
Anticancer Res; 2000; 20(3B):2009-13. PubMed ID: 10928143
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of CD68 and kallikrein 6 in human glioma.
Strojnik T; Kavalar R; Zajc I; Diamandis EP; Oikonomopoulou K; Lah TT
Anticancer Res; 2009 Aug; 29(8):3269-79. PubMed ID: 19661345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
